-
- Kouji Banno
- Department of Obstetrics and Gynecology, School of Medicine, Keio University, Shinanomachi 35, Shinjuku-ku, Tokyo 160-8582, Japan
-
- Megumi Yanokura
- Department of Obstetrics and Gynecology, School of Medicine, Keio University, Shinanomachi 35, Shinjuku-ku, Tokyo 160-8582, Japan
-
- Miho Iida
- Department of Obstetrics and Gynecology, School of Medicine, Keio University, Shinanomachi 35, Shinjuku-ku, Tokyo 160-8582, Japan
-
- Masataka Adachi
- Department of Obstetrics and Gynecology, School of Medicine, Keio University, Shinanomachi 35, Shinjuku-ku, Tokyo 160-8582, Japan
-
- Kanako Nakamura
- Department of Obstetrics and Gynecology, School of Medicine, Keio University, Shinanomachi 35, Shinjuku-ku, Tokyo 160-8582, Japan
-
- Yuya Nogami
- Department of Obstetrics and Gynecology, School of Medicine, Keio University, Shinanomachi 35, Shinjuku-ku, Tokyo 160-8582, Japan
-
- Kiyoko Umene
- Department of Obstetrics and Gynecology, School of Medicine, Keio University, Shinanomachi 35, Shinjuku-ku, Tokyo 160-8582, Japan
-
- Kenta Masuda
- Department of Obstetrics and Gynecology, School of Medicine, Keio University, Shinanomachi 35, Shinjuku-ku, Tokyo 160-8582, Japan
-
- Iori Kisu
- Department of Obstetrics and Gynecology, School of Medicine, Keio University, Shinanomachi 35, Shinjuku-ku, Tokyo 160-8582, Japan
-
- Hiroyuki Nomura
- Department of Obstetrics and Gynecology, School of Medicine, Keio University, Shinanomachi 35, Shinjuku-ku, Tokyo 160-8582, Japan
-
- Fumio Kataoka
- Department of Obstetrics and Gynecology, School of Medicine, Keio University, Shinanomachi 35, Shinjuku-ku, Tokyo 160-8582, Japan
-
- Eiichiro Tominaga
- Department of Obstetrics and Gynecology, School of Medicine, Keio University, Shinanomachi 35, Shinjuku-ku, Tokyo 160-8582, Japan
-
- Daisuke Aoki
- Department of Obstetrics and Gynecology, School of Medicine, Keio University, Shinanomachi 35, Shinjuku-ku, Tokyo 160-8582, Japan
抄録
<jats:p>Ovarian cancer has a poor prognosis because early detection is difficult and recurrent ovarian cancer is usually drug-resistant. The morbidity and mortality of ovarian cancer are high worldwide and new methods of diagnosis and therapy are needed. MicroRNAs (miRNAs) are posttranscriptional regulators of gene expression that are involved in carcinogenesis, metastasis, and invasion. Thus, miRNAs are likely to be useful as diagnostic and prognostic biomarkers and for cancer therapy. Many miRNAs have altered expression in ovarian cancer compared to normal ovarian tissues and these changes may be useful for diagnosis and treatment. For example, deficiencies of enzymes including Dicer and Drosha that are required for miRNA biogenesis may be adverse prognostic factors; miRNAs such as miR-214 and miR-31, which are involved in drug resistance, and the miR-200 family, which is implicated in metastasis, may serve as biomarkers; and transfection of downregulated miRNAs and inhibition of upregulated miRNAs may be effective for treatment of ovarian cancer. Chemotherapy targeting epigenetic mechanisms associated with miRNAs may also be effective to reverse gene silencing.</jats:p>
収録刊行物
-
- BioMed Research International
-
BioMed Research International 2014 1-6, 2014
Hindawi Limited
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1360567186300030592
-
- ISSN
- 23146141
- 23146133
-
- データソース種別
-
- Crossref
- KAKEN